;PMID: 2437946 ;source_file_2838.mrg ;Release 0.9 of PennBioIE ;Funded by NSF ITR EIA-0205448 ;0)section:[e:0..36] = [t:0..36] ;1)sentence:[e:42..128] = [t:42..128] ;2)section:[e:132..260] = [t:132..260] ;3)sentence:[e:264..432] = [t:264..432] ;4)sentence:[e:433..600] = [t:433..600] ;5)sentence:[e:601..693] = [t:601..693] ;6)sentence:[e:694..809] = [t:694..809] ;7)sentence:[e:810..900] = [t:810..900] ;8)sentence:[e:901..1006] = [t:901..1006] ;9)sentence:[e:1007..1146] = [t:1007..1146] ;10)sentence:[e:1147..1268] = [t:1147..1268] ;11)section:[e:1272..1316] = [t:1272..1316] ;section 0 Span:0..36 ;Br J Cancer. 1987 Apr;55(4):407-11. (SEC (FRAG (NNP:[0..2] Br) (NNP:[3..4] J) (NNP:[5..11] Cancer) (.:[11..12] .) (CD:[14..18] 1987) (NNP:[19..22] Apr) (::[22..23] ;) (CD:[23..25] 55) (-LRB-:[25..26] -LRB-) (CD:[26..27] 4) (-RRB-:[27..28] -RRB-) (::[28..29] :) (CD:[29..35] 407-11) (.:[35..36] .))) ;sentence 1 Span:42..128 ;Biological properties of a tumour cell line (NB1-G) derived from human ;neuroblastoma. ;[114..127]:malignancy-type:"neuroblastoma" (SENT (NP-HLN (NP (JJ:[42..52] Biological) (NNS:[53..63] properties)) (PP (IN:[64..66] of) (NP (NP (NP (DT:[67..68] a) (NN:[69..75] tumour) (NN:[76..80] cell) (NN:[81..85] line)) (NP (-LRB-:[86..87] -LRB-) (NN:[87..92] NB1-G) (-RRB-:[92..93] -RRB-))) (VP (VBN:[94..101] derived) (NP (-NONE-:[101..101] *)) (PP (IN:[102..106] from) (NP (JJ:[107..112] human) (NN:[114..127] neuroblastoma)))))) (.:[127..128] .))) ;section 2 Span:132..260 ;Carachi R, Raza T, Robertson D, Wheldon TW, Wilson L, Livingstone A, van ;Heyningen V, Spowart G, Middleton P, Gosden JR, et al. (SEC (FRAG (NNP:[132..139] Carachi) (NNP:[140..141] R) (,:[141..142] ,) (NNP:[143..147] Raza) (NNP:[148..149] T) (,:[149..150] ,) (NNP:[151..160] Robertson) (NNP:[161..162] D) (,:[162..163] ,) (NNP:[164..171] Wheldon) (NNP:[172..174] TW) (,:[174..175] ,) (NNP:[176..182] Wilson) (NNP:[183..184] L) (,:[184..185] ,) (NNP:[186..197] Livingstone) (NNP:[198..199] A) (,:[199..200] ,) (NNP:[201..204] van) (NNP:[206..215] Heyningen) (NNP:[216..217] V) (,:[217..218] ,) (NNP:[219..226] Spowart) (NNP:[227..228] G) (,:[228..229] ,) (NNP:[230..239] Middleton) (NNP:[240..241] P) (,:[241..242] ,) (NNP:[243..249] Gosden) (NNP:[250..252] JR) (,:[252..253] ,) (NNP:[254..256] et) (FW:[257..259] al) (.:[259..260] .))) ;sentence 3 Span:264..432 ;The properties of a new tumour cell line (NB1-G) derived from human ;neuroblastoma by xenografting in nude rats followed by adaptation to tissue ;culture are described. ;[333..346]:malignancy-type:"neuroblastoma" (SENT (S (NP-SBJ-1 (NP (DT:[264..267] The) (NNS:[268..278] properties)) (PP (IN:[279..281] of) (NP (NP (NP (DT:[282..283] a) (JJ:[284..287] new) (NN:[288..294] tumour) (NN:[295..299] cell) (NN:[300..304] line)) (NP (-LRB-:[305..306] -LRB-) (NN:[306..311] NB1-G) (-RRB-:[311..312] -RRB-))) (VP (VBN:[313..320] derived) (NP (-NONE-:[320..320] *)) (PP (IN:[321..325] from) (NP (JJ:[326..331] human) (NN:[333..346] neuroblastoma))) (PP-MNR (IN:[347..349] by) (NP (NP (NP (NN:[350..362] xenografting)) (PP-LOC (IN:[363..365] in) (NP (JJ:[366..370] nude) (NNS:[371..375] rats)))) (VP (VBN:[376..384] followed) (NP (-NONE-:[384..384] *)) (PP (IN:[385..387] by) (NP-LGS (NP (NN:[388..398] adaptation)) (PP (TO:[399..401] to) (NP (NML (NN:[402..408] tissue) (NN:[410..417] culture))))))))))))) (VP (VBP:[418..421] are) (VP (VBN:[422..431] described) (NP-1 (-NONE-:[431..431] *)))) (.:[431..432] .))) ;sentence 4 Span:433..600 ;Studies using a panel of monoclonal antibodies demonstrate the ;neuro-ectodermal nature of the cells and support the diagnosis of the ;primary tumour as neuroblastoma. ;[458..479]:gene-protein:"monoclonal antibodies" ;[568..575]:malignancy-clinical-stage:"primary" ;[576..582]:malignancy-type:"tumour" ;[586..599]:malignancy-type:"neuroblastoma" (SENT (S (NP-SBJ (NP (NNS:[433..440] Studies)) (VP (VBG:[441..446] using) (NP (NP (DT:[447..448] a) (NN:[449..454] panel)) (PP (IN:[455..457] of) (NP (JJ:[458..468] monoclonal) (NNS:[469..479] antibodies)))))) (VP (VP (VBP:[481..492] demonstrate) (NP (NP (DT:[493..496] the) (ADJP (AFX:[497..502] neuro) (HYPH:[502..503] -) (JJ:[503..513] ectodermal)) (NN:[514..520] nature)) (PP (IN:[521..523] of) (NP (DT:[524..527] the) (NNS:[528..533] cells))))) (CC:[534..537] and) (VP (VBP:[538..545] support) (NP (NP (DT:[546..549] the) (NN:[550..559] diagnosis)) (PP (IN:[561..563] of) (NP (DT:[564..567] the) (JJ:[568..575] primary) (NN:[576..582] tumour))) (PP (IN:[583..585] as) (NP (NN:[586..599] neuroblastoma)))))) (.:[599..600] .))) ;sentence 5 Span:601..693 ;Cytogenetic studies have revealed a human karyotype with several chromosomal ;abnormalities. (SENT (S (NP-SBJ (JJ:[601..612] Cytogenetic) (NNS:[613..620] studies)) (VP (VBP:[621..625] have) (VP (VBN:[626..634] revealed) (NP (NP (DT:[635..636] a) (JJ:[638..643] human) (NN:[644..653] karyotype)) (PP (IN:[654..658] with) (NP (JJ:[659..666] several) (JJ:[667..678] chromosomal) (NNS:[679..692] abnormalities)))))) (.:[692..693] .))) ;sentence 6 Span:694..809 ;Genetic analysis by in situ DNA hybridization has demonstrated the presence ;of multiple copies of the N-myc gene. ;[798..803]:gene-rna:"N-myc" (SENT (S (NP-SBJ (NP (JJ:[694..701] Genetic) (NN:[702..710] analysis)) (PP (IN:[711..713] by) (NP (ADJP (FW:[714..716] in) (FW:[718..722] situ)) (NN:[723..726] DNA) (NN:[727..740] hybridization)))) (VP (VBZ:[741..744] has) (VP (VBN:[745..757] demonstrated) (NP (NP (DT:[758..761] the) (NN:[762..770] presence)) (PP (IN:[771..773] of) (NP (NP (JJ:[774..782] multiple) (NNS:[783..789] copies)) (PP (IN:[790..792] of) (NP (DT:[793..796] the) (NN:[798..803] N-myc) (NN:[804..808] gene)))))))) (.:[808..809] .))) ;sentence 7 Span:810..900 ;Approximately 20-30 fold amplification of the gene is observed on Southern ;blot analysis. ;[835..848]:variation-type:"amplification" ;[852..860]:gene-rna:"the gene" (SENT (S (NP-SBJ-1 (NP (QP (RB:[810..823] Approximately) (CD:[824..826] 20) (HYPH:[826..827] -) (CD:[827..829] 30) (JJ:[830..834] fold)) (NN:[835..848] amplification)) (PP (IN:[849..851] of) (NP (DT:[852..855] the) (NN:[856..860] gene)))) (VP (VBZ:[861..863] is) (VP (VBN:[864..872] observed) (NP-1 (-NONE-:[872..872] *)) (PP (IN:[873..875] on) (NP (NML (JJ:[877..885] Southern) (NN:[886..890] blot)) (NN:[891..899] analysis))))) (.:[899..900] .))) ;sentence 8 Span:901..1006 ;The cell line has been adapted to growth as multicellular tumour spheroids ;as well as monolayer culture. (SENT (S (NP-SBJ-1 (DT:[901..904] The) (NN:[905..909] cell) (NN:[910..914] line)) (VP (VBZ:[915..918] has) (VP (VBN:[919..923] been) (VP (VBN:[924..931] adapted) (NP-1 (-NONE-:[931..931] *)) (PP (TO:[932..934] to) (NP (NP (NN:[935..941] growth)) (PP (IN:[942..944] as) (NP (NP (JJ:[946..959] multicellular) (NN:[960..966] tumour) (NNS:[967..976] spheroids)) (CONJP (RB:[977..979] as) (RB:[980..984] well) (IN:[985..987] as)) (NP (NN:[988..997] monolayer) (NN:[998..1005] culture))))))))) (.:[1005..1006] .))) ;sentence 9 Span:1007..1146 ;Radiobiological studies on spheroids show the cells to be radiosensitive ;with low capacity for sub-lethal damage accumulation and repair. (SENT (S (NP-SBJ (NP (JJ:[1007..1022] Radiobiological) (NNS:[1024..1031] studies)) (PP (IN:[1032..1034] on) (NP (NNS:[1035..1044] spheroids)))) (VP (VBP:[1045..1049] show) (S (NP-SBJ (DT:[1050..1053] the) (NNS:[1054..1059] cells)) (VP (TO:[1060..1062] to) (VP (VB:[1063..1065] be) (ADJP-PRD (JJ:[1066..1080] radiosensitive)) (PP (IN:[1081..1085] with) (NP (NP (JJ:[1086..1089] low) (NN:[1090..1098] capacity)) (PP (IN:[1099..1102] for) (NP (NP (NML-1 (ADJP (AFX:[1104..1107] sub) (HYPH:[1107..1108] -) (JJ:[1108..1114] lethal)) (NN:[1115..1121] damage)) (NN:[1122..1134] accumulation)) (CC:[1135..1138] and) (NP (NML-1 (-NONE-:[1138..1138] *P*)) (NN:[1139..1145] repair)))))))))) (.:[1145..1146] .))) ;sentence 10 Span:1147..1268 ;The cell line should be useful for fundamental studies of human ;neuroblastoma as well as experimental therapy in vitro. ;[1212..1225]:malignancy-type:"neuroblastoma" (SENT (S (NP-SBJ (DT:[1147..1150] The) (NN:[1151..1155] cell) (NN:[1156..1160] line)) (VP (MD:[1161..1167] should) (VP (VB:[1168..1170] be) (ADJP-PRD (JJ:[1171..1177] useful)) (PP (IN:[1178..1181] for) (NP (NP (JJ:[1183..1194] fundamental) (NNS:[1195..1202] studies)) (PP (IN:[1203..1205] of) (NP (NP (NP (JJ:[1206..1211] human) (NN:[1212..1225] neuroblastoma)) (CONJP (RB:[1226..1228] as) (RB:[1229..1233] well) (IN:[1234..1236] as)) (NP (JJ:[1237..1249] experimental) (NN:[1250..1257] therapy))) (ADVP (FW:[1258..1260] in) (FW:[1262..1267] vitro)))))))) (.:[1267..1268] .))) ;section 11 Span:1272..1316 ;PMID: 2437946 [PubMed - indexed for MEDLINE] (SEC (FRAG (NNP:[1272..1276] PMID) (::[1276..1277] :) (CD:[1278..1285] 2437946) (NN:[1286..1287] -LSB-) (NNP:[1287..1293] PubMed) (::[1294..1295] -) (NN:[1296..1303] indexed) (IN:[1304..1307] for) (NNP:[1308..1315] MEDLINE) (-RRB-:[1315..1316] -RSB-)))